Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein

European Journal of Pharmacology

Volumn 472, Issue 1-2, 2003, Pages 33-38

  Zhang, Jean Y ^a   Nawoschik, Stanley ^a   Kowal, Dianne ^a   Smith, Deborah ^a   Spangler, Taylor ^a   Ochalski, Rafal ^a   Schechter, Lee ^a   Dunlop, John ^a  

^a PFIZER INC   (United States)

Author keywords

5 HT6 receptor; Ca2+ signaling; Chimeric G protein; FLIPR; Fluorometric imaging plate reader

Indexed keywords

5 CARBAMOYLTRYPTAMINE; 5 CHLORO 3 METHYLBENZO[B]THIOPHENE 2 SULFONIC ACID(4 METHOXY 3 PIPERAZIN 1 YLPHENYL)AMIDE; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; 5 METHOXYTRYPTAMINE; ARIPIPRAZOLE; CALCIUM ION; CLOZAPINE; CYCLIC AMP; DOPAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; LISURIDE; NEUROLEPTIC AGENT; SEROTONIN; SEROTONIN 6 RECEPTOR; TRYPTAMINE; UNCLASSIFIED DRUG; CALCIUM; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HYBRID PROTEIN; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ARTICLE; CALCIUM SIGNALING; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; EMBRYO CELL; FEASIBILITY STUDY; FLUOROMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CELL; PRIORITY JOURNAL; CELL LINE; GENETICS; METABOLISM;

CALCIUM; CALCIUM SIGNALING; CELL LINE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HUMANS; RECEPTORS, SEROTONIN; RECOMBINANT FUSION PROTEINS; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; TRANSFECTION;

EID: 0037967716     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01855-7     Document Type: Article

References (31)

1. Bentley J.C., Bourson A., Boess F.G., Fone K.C., Marsden C.A., Petit N., Sleight A.J. Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist Ro 04-6790 in rats. Br. J. Pharmacol. 126:1999;1537-1542.
2. Boess F.G., Monsma F.J., Caralo C., Meyer V., Rudler A., Zwingelstein C., Sleight A.J. Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK-293 cells. Neuropharmacology. 36:1997;713-720.
3. Bourson A., Borroni E., Austin R.H., Monsma F.J., Sleight A.J. Determination of the role of the 5-HT6 receptor in the rat brain: a study using antisense oligonucleotides. J. Pharmacol. Exp. Ther. 274:1995;173-180.
4. Brough S.J., Jerman J.C., Jewitt F., Smart D. Characterization of an endogenous bombesin receptor in CHO/DG44 cells. Eur. J. Pharmacol. 409:2000;259-263.
5. Conklin B.R., Bourne H.R. Structural elements of G alpha subunits that interact with G beta gamma, receptors, and effectors. Cell. 73:1993;631-641.
6. Conklin B.R., Farfel Z., Lustig K.D., Julius D., Bourne H.R. Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. Nature. 363:1993;274-276.
7. Conklin B.R., Herzmark P., Ishida S., Voyno-Yasenetskaya T.A., Sun Y., Farfel Z., Bourne H.R. Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation. Mol. Pharmacol. 50:1996;885-890.
8. αi-coupled receptors. Anal. Biochem. 270:1999;242-248.
9. Gerard C., Mestikawy S.E., Lebrand C., Adrien J., Ruat M., Traiffort E., Hamon M., Martres M.-P. Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytrptamine treated rats. Synapse. 23:1996;164-173.
10. αz is required for receptor recognition, whereas its alpha 4/beta 6 loop is essential for inhibition of adenylyl cyclase. Mol. Pharmacol. 58:2000;993-1000.
11. 2 receptor subtypes. Eur. J. Pharmacol. 414:2001;23-30.
12. Jordan J., Koprivica V., Chen R., Tottori K., Kikuchi T., Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur. J. Pharmacol. 441:2002;137-140.
13. Kohen R., Metcalf M.A., Khan N., Druck T., Huebner K., Lachowicz J.E., Meltzer H.Y., Sibley D.R., Roth B.L., Hamblin M.W. Cloning, characterization and chromosomal localization of a human 5-HT6 serotonin receptor. J. Neurochem. 66:1996;47-56.
14. αq is critical for constraining the selectivity of receptor coupling. J. Biol. Chem. 272:1997;19107-19110.
15. 2+ assays. J. Biomol. Screen. 4:1999;249-258.
16. Monsma F.J., Shen Y., Ward R.P., Hamblin M.W., Sibley D.R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 43:1993;320-327.
17. Patel K., Barnes A., Camacho J., Paterson C., Boughtflower R., Cousens D., Marshall F. Activity of diadenosine polyphosphates at P2Y receptors stably expressed in 1321N1 cells. Eur. J. Pharmacol. 430:2001;203-210.
18. Porter R.H.P., Benwell K.R., Lamb H., Malcolm C.S., Allen N.H., Revell D.F., Adams D.R., Sheardown M.J. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. Br. J. Pharmacol. 128:1999;13-20.
19. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma F.J., Shen Y., Meltzer H.Y., Sibley D.R. Binding of typical and atypical antipsychotic agents to 5-hydroxytrptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmacol. Exp. Ther. 268:1994;1403-1410.
20. Routledge C., Bromidge S.M., Moss S.F., Price G.W., Hirst W., Newman H., Riley G., Gager T., Stean T., Upton N., Clarke S.E., Brown A.M., Middlemiss D.N. Characterization of SB-271046: a potent, selective and orally active 5-HT6 receptor antagonist. Br. J. Pharmacol. 130:2000;1606-1612.
21. Simpson P.B., Woollacott A.J., Hill R.G., Seabrook G.R. Functional characterization of bradykinin analogs on recombinant human bradykinin B-1 and B-2 receptors. Eur. J. Pharmacol. 392:2000;1-9.
22. Sleight A.J., Boess F.G., Bos M., Levet-Trafit B., Riemer C., Bourson A. Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors. Br. J. Pharmacol. 124:1998;556-562.
23. Smart D., Jerman J.C., Brough S.J., Rushton S.L., Murdock P.R., Jewitt F., Elshourbagy N.A., Ellis C.E., Middlemiss D.N., Brown F. Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell line using FLIPR. Br. J. Pharmacol. 128:1999;1-3.
24. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 129:2000;227-230.
25. Smart D., Jerman J.C., Brough S.J., Neville W.A., Jewitt F., Porter R.A. The hypocretins are weak agonists at recombinant human orexin-1 and orexin-2 receptors. Br. J. Pharmacol. 129:2000;1289-1291.
26. Smart D., Jerman J.C., Gunthorpe M.J., Brough S.J., Ranson J., Cairns W., Hayes P.D., Randall A.D., Davis J.B. Characterization using FLIPR of human vanilloid receptor pharmacology. Eur. J. Pharmacol. 417:2001;51-58.
27. Smart D., Sabido-David C., Brough S.J., Jewitt F., Johns A., Porter R.A., Jerman J.C. SB-334867-A: the first selective orexin-1 receptor antagonist. Br. J. Pharmacol. 132:2001;1179-1182.
28. Taylor D.M. Aripiprazole: a review of its pharmacology and clinical use. Int. J. Clin. Pract. 57:2003;49-54.
29. 3 receptor. J. Pharmacol. Exp. Ther. 301:2002;451-458.
30. 7 receptor. Eur. J. Pharmacol. 396:2000;1-8.
31. (B2) heterodimeric recombinant receptor shows low sensitivity to phaclofen and saclofen. Br. J. Pharmacol. 131:2000;1050-1054.